Skip to main content
Microba Life Sciences banner
Microba Life Sciences logo

Microba Life Sciences

Microba Life Sciences is a precision microbiome science company powering medical innovation to transform human health.

Backed by

MacrogenMacrogen

Raised 2.85M EQUITY on June 12, 2019

About

Microba operates whole‑genome shotgun sequencing and bioinformatics pipelines with a gut microbiome database for microbial discovery, metabolite analysis, and collaborative microbiome service deployments.

Mission

Microba specializes in genetic analysis of the gut microbiome, with a bioinformatics pipeline and database that the article describes as best in its field. The company was established in 2017 by faculties of Queensland University and has accumulated research data and related intellectual property. Microba’s core product work focuses on whole-genome (shotgun) sequencing of gut microorganisms rather than 16S rRNA targeted approaches, enabling novel microorganism discovery and metabolite analysis. The company is partnering with Macrogen to co-develop a microbiome service and to build a microbiome database in Asia Pacific (including Korea, Japan, and Singapore). Microba and Macrogen plan a global service launch in early 2020 and expect to target launches in the US and Asia Pacific. Microba is pursuing licensing deals with multinational pharmaceutical companies to support therapeutics research and commercialisation.

Quick Facts

Founded

2017

Funding

EQUITY

Industry

Biotechnology, Genetics, Health Care, Life Science, Wellness

Team Size

51-100

Headquarters

Brisbane, Queensland, Australia